Inactive Instrument

News Fibrocell Science Inc Nyse

Equities

US3157212099

End-of-day quote Nyse Other stock markets
- ^USD	-

2019	Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from S&P TMI Index	CI
2019	Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from NASDAQ Composite Index	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fibrocell Science : Castle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science	17/12/19	AQ
Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from S&P TMI Index	16/12/19	CI
FIBROCELL SCIENCE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	13/12/19	AQ
Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from NASDAQ Composite Index	13/12/19	CI
Castle Creek Pharmaceutical Holdings, Inc. completed the acquisition of Fibrocell Science, Inc..	12/12/19	CI
FIBROCELL SCIENCE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	10/12/19	AQ
FIBROCELL SCIENCE, INC. : Other Events (form 8-K)	22/11/19	AQ
Fibrocell Science, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	14/11/19	CI
FIBROCELL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fibrocell Science, Inc. - FCSC	17/09/19	BU
Castle Creek Pharmaceutical Holdings, Inc. entered into a definitive agreement to acquire Fibrocell Science, Inc. for $63.3 million.	11/09/19	CI
Fibrocell Science, Inc Appoints Sean D. Buckley as Chief Financial Officer	22/08/19	CI
Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights	14/08/19	GL
Fibrocell Science, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	14/08/19	CI
Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB	29/05/19	GL
Fibrocell Science, Inc. Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB	29/05/19	CI
Fibrocell Science, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	15/05/19	CI
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy	15/04/19	GL
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy	15/04/19	CI
Fibrocell Science, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	27/03/19	CI
Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007	27/03/19	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Fibrocell Science Inc Nyse

Equities

US3157212099

Summary

Filters